Business Context and Reporting Period
This Form 8-K, dated March 15, 2021, reports the completion of a merger between Anchiano Therapeutics Ltd. and Chemomab Ltd. on March 16, 2021. Following the merger, Anchiano changed its name to Chemomab Therapeutics Ltd. (the "Company"). The Company is a clinical-stage biotech firm focused on developing therapeutics for inflammation and fibrosis. The filing also details a concurrent private placement financing and a 4:1 reverse share split.
Key Financial Metrics and Capital Structure
- Private Placement Proceeds: The Company sold approximately $45.5 million in American Depositary Shares (ADSs) and accompanying warrants in a private placement.
- Securities Issued: 41,915,433 ADSs and 4,191,543 warrants were issued at a price of $1.08443 per ADS (pre-reverse split).
- Warrant Potential: Full exercise of the warrants would generate an additional approximately $4.5 million in proceeds.
- Asset Sale: The Company sold its pan-RAS and PDE10/beta-catenin programs to Kestrel Therapeutics, Inc. for $1 million, expected to close on March 31, 2021.
- Share Capital: Registered share capital increased from 500,000,000 to 650,000,000 ordinary shares. Post-merger, there are approximately 10,697,975 outstanding ADSs.
- Ownership Structure: Pre-merger Chemomab shareholders own approximately 90% of the Company; pre-merger Anchiano shareholders own approximately 10%.
Note: This filing does not provide specific revenue, profit, cash flow, or debt figures for the reporting period. Pro forma financial information is scheduled to be filed within 71 days.
Material Changes Versus Prior Period
- Corporate Identity: The Company changed its name from Anchiano Therapeutics Ltd. to Chemomab Therapeutics Ltd.
- Trading Symbol: The ticker symbol changed from "ANCN" to "CMMB" on the Nasdaq Capital Market, effective March 17, 2021.
- Share Structure: A 4:1 reverse share split was effected, and the number of ordinary shares per ADS increased from 5 to 20.
- Valuation Basis: The merger exchange ratio was calculated based on a $135.0 million valuation for Chemomab and a $15.0 million valuation for Anchiano.
- Portfolio Change: The Company divested its pan-RAS and PDE10/beta-catenin programs to Kestrel Therapeutics.
Management Commentary, Governance, and Risks
Management Changes: Adi Mor was appointed Chief Executive Officer and Chief Scientific Officer. Sigal Fattal was appointed interim Chief Financial Officer, and Aaron Aharon was appointed Chief Medical Officer. Neil Cohen resigned as interim CEO but remains on the Board.
Board Composition: The Board was reconstituted with a classified structure. New directors include Stephen Squinto (Chairman), Adi Mor, Nissim Darvish, Joel Maryles, Alan Moses, and Claude Nicaise. Former directors Stanislav Polovets, Ruth Alon, and Isaac Kohlberg resigned.
Shareholder Approval: Shareholders approved the merger, the private placement, the amended articles of association, and various compensation and indemnification proposals at a special meeting on March 15, 2021.
Risks and Contingencies: The private placement is exempt from registration under Section 4(a)(2) and Rule 506 of Regulation D. The Company is obligated to file a registration statement for the resale of shares within 30 days of the closing. The filing notes that representations in the purchase agreement are qualified by confidential disclosure schedules and may change.
Investor Verification Checklist
- Verify the final closing date and total net proceeds of the $45.5 million private placement.
- Confirm the exact number of outstanding shares and ADSs post-reverse split and post-merger.
- Review the upcoming pro forma financial statements (due within 71 days) for combined liquidity and cash position.
- Monitor the closing of the $1 million asset sale to Kestrel Therapeutics scheduled for March 31, 2021.
- Check the filing of the Registration Statement for the resale of private placement shares within the 30-day window.